Krystal Biotech Inc (KRYS) - Total Assets
Based on the latest financial reports, Krystal Biotech Inc (KRYS) holds total assets worth $1.40 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check KRYS total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Krystal Biotech Inc - Total Assets Trend (2016–2025)
This chart illustrates how Krystal Biotech Inc's total assets have evolved over time, based on quarterly financial data. Explore how much of Krystal Biotech Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Krystal Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Krystal Biotech Inc's total assets of $1.40 Billion consist of 76.8% current assets and 23.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.2% |
| Accounts Receivable | $127.42 Million | 9.6% |
| Inventory | $40.48 Million | 3.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Krystal Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Krystal Biotech Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Krystal Biotech Inc's current assets represent 76.8% of total assets in 2025, a decrease from 99.4% in 2016.
- Cash Position: Cash and equivalents constituted 37.2% of total assets in 2025, down from 88.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 9.6% of total assets.
Krystal Biotech Inc Competitors by Total Assets
Key competitors of Krystal Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
|
Galecto Inc
NASDAQ:GLTO
|
USA | $535.44 Million |
Krystal Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.46 | 9.65 | 20.42 |
| Quick Ratio | 9.06 | 9.27 | 20.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $911.94 Million | $687.31 Million | $351.81 Million |
Krystal Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Krystal Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.06 |
| Latest Market Cap to Assets Ratio | 6.92 |
| Asset Growth Rate (YoY) | 26.3% |
| Total Assets | $1.33 Billion |
| Market Capitalization | $9.22 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Krystal Biotech Inc's assets at a significant premium (6.92x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Krystal Biotech Inc's assets grew by 26.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Krystal Biotech Inc (2016–2025)
The table below shows the annual total assets of Krystal Biotech Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.33 Billion | +26.33% |
| 2024-12-31 | $1.06 Billion | +29.02% |
| 2023-12-31 | $818.36 Million | +46.54% |
| 2022-12-31 | $558.45 Million | -10.83% |
| 2021-12-31 | $626.29 Million | +101.48% |
| 2020-12-31 | $310.84 Million | +48.71% |
| 2019-12-31 | $209.02 Million | +80.01% |
| 2018-12-31 | $116.12 Million | +131.70% |
| 2017-12-31 | $50.11 Million | +2196.70% |
| 2016-12-31 | $2.18 Million | -- |
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystro… Read more